Physician profile
Asha Kumar
NPI 1740395763
$1,153.43
in general payments reported to CMS, 2019-2025
15 companies · $30.06 in 2025
The $30.06 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $8.00 · 2021: $190 · 2022: $109 · 2023: $281 · 2024: $383 · 2025: $30.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $266.40 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $148.23 | 2024 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $124.99 | 2021 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
| Omeros Corporation | $109.21 | 2019 | |
| Biotissue Holdings INC. | $99.03 | 2020-2025 | |
| Abbvie INC. | $63.94 | 2023 | |
| Sight Sciences, INC. | $52.06 | 2021-2023 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $38.51 | 2019-2023 | Cequa, Xelpros |
| Alcon Vision LLC | $29.37 | 2019-2023 | Simbrinza |
| Astellas Pharma US INC | $25.91 | 2024 | Izervay |
| Eyepoint US, INC. | $24.20 | 2022 | |
| Kala Pharmaceuticals, INC. | $17.90 | 2021 | |
| Dompe US, INC. | $17.35 | 2022 | |
| Aerie Pharmaceuticals, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.